Happy Friday. I scan 100+ Chinese-language sources every day, the WeChat accounts and Bilibili channels and finance wires that English coverage of China AI mostly skips, and I write up the signal I find. Let's go.
The Repricing
The number that should stop you is 460. From January to June, Chinese embodied-AI companies raised about ¥46 billion across the first half of 2026, with twenty firms taking roughly 70% of it. Stretch the window to a full year, July 2025 through June 2026, and a count from IT桔子 (the Chinese Crunchbase) reaches 503 financing rounds and more than ¥96 billion, per a 36Kr breakdown published this week. That is more than one round a day, every day, for a year, in a single category of Chinese startup.
But the headline number is not the story. The story is what the money started asking for on its way in.
A year ago, a Chinese robotics founder needed a pedigree, a technology roadmap, and a vision. In 2026 the questions changed. One first-tier investor told 36Kr that the things he now asks before writing a check are "do customers repurchase, how many hours can the robot run continuously, what is the failure rate." Those used to be footnotes in due diligence. Now they decide the deal. The phrase the Chinese coverage keeps using is 从看故事到看数据, from reading the story to reading the data, and it marks the moment a hype category turns into an industry that has to clear a bar.
You can see the bar in where the money concentrated. Round counts in embodied AI actually fell 31.7% year over year in the second half of 2025, while the average check size rose 46.8%. Fewer companies, bigger checks. A ¥10-billion valuation is becoming the entry ticket to the main financing circle, and the mid-tier component makers (joint modules, sensors, harmonic reducers) that got funded every few days last year are quietly running dry. The single largest round of the cycle went to Tareeya (它石智航), a company building robot "brains," which closed $455 million in April led by Hillhouse and Sequoia China, the biggest single embodied-AI round in Chinese history. Galbot took ¥2.5 billion. Robovision (自变量机器人) took nearly ¥2 billion. The money is not spreading. It is stacking on the few firms that can already show a number.
Here is why this is the lead and not a funding roundup. Three years of Chinese AI investment ran on the bet that the technology would eventually work. This cycle is the first one priced on whether it works now. When the question shifts from "could this be huge" to "show me the repurchase rate," you are watching a market grow up in real time. The hard part is that embodied AI may be the worst-suited thing in tech to value this way. A robot that can only dance today might learn a real industrial task next quarter, and the value compounds non-linearly with the data it collects. So investors are doing two contradictory things at once, using failure rates and reorder rates to screen out the companies that can only tell a story, while leaving room for the compounding upside on the handful that can do both. The firms that satisfy both demands are, by definition, the leaders. Which is exactly why the money stacks on them.
That repricing is the thread running through almost everything else today.
The Briefing
The same investors who back the robots now want them back from Meta. The Information reported that Manus's original Chinese backers, Tencent, Sequoia China, and ZhenFund, plan to spend $2 billion buying the company back at the exact price Meta paid to acquire it last December. China's NDRC blocked Meta's purchase in April on foreign-investment-security grounds, and now the sellers are reversing the trade. The detail that matters is the structure. Manus is weighing a China-onshore Sino-foreign joint venture to let the Chinese investors hold the stock cleanly and to lay track for a Hong Kong IPO. The financial logic is brutal and simple: Manus's annualized revenue has run from about $100 million at acquisition to $400-500 million now, four to five times in roughly six months, so buying back at the old price is a discount. The buyback-plus-JV-plus-HK-listing combination is becoming the template for unwinding a blocked cross-border deal, and Chinese capital ends up owning more of the company than it did before Meta showed up.
An autonomous-driving unicorn is reading the same exit map. Momenta, the Suzhou self-driving company backed by GM, Toyota, and SAIC, is preparing a Hong Kong IPO at roughly a $9 billion valuation, targeting about $1 billion raised, according to Sina's market wire. Hong Kong, not New York, is where Chinese AI hardware lists now, and the pipeline behind Momenta (humanoid makers, chip firms, model labs) is filling the same exchange. The venue is the geopolitics. With the Nasdaq path effectively closed, HKEX is absorbing the entire wave.
The capital wave reached the ocean floor. Shihang Intelligence (世航智能), an underwater-robotics company, closed an A round above ¥1 billion, which 36Kr reports is the largest single round in ocean robotics anywhere in the world. The backers tell you how vertical this is getting: the round was led in part by the industrial funds of two domestic GPU makers, Moore Threads and Kunlunxin, alongside Singapore's Vertex Growth, and Zhu Xiaohu's GSR Ventures put in money for the fifth time. Chip companies are now funding the robots that will eventually run on their chips. Shihang's hardware already works to full ocean depth, 0 to 10,000 meters, on ship-hull cleaning, offshore-wind inspection, and underwater security, and it booked more than ¥1 billion in orders in the first half. Orders, not demos. That is the data the new money is paying for.
The application layer set its own record. Evoken (演语科技, formerly Liblib) disclosed a B+ round of nearly $300 million at a valuation above $2 billion, the largest Chinese AI-application financing of the year. The number that earned it. ARR hit $300 million in May, up nearly threefold in a few months, on AI video generation. The check the company raised is roughly the size of its annual revenue. When a Chinese AI-application company is priced at a clean multiple of real recurring revenue rather than a story about future scale, that is the repricing showing up on the software side too.
Signals
Tang Jie told Musk nine months is too long. After the US barred sales of Anthropic's Mythos model to China, someone on X asked Elon Musk when China would catch up. Musk said nine months. Zhipu chief scientist Tang Jie replied that it would not take that long, pointing to GLM-5.2, which Zhipu shipped this week with benchmarks closing on the frontier. The interesting wrinkle in the Chinese coverage is that the base model is only half the gap. The other half is post-training, the fine-tuning layer where GLM-5.1 to 5.2 made most of its jump, and almost no one in China is set up to do it on the newest bases yet.
DeepSeek's image mode could not recognize its own founder. DeepSeek rolled out a vision feature this week, and within a day Chinese users found it identifying founder Liang Wenfeng as ByteDance's Zhang Yiming. It trended on Baidu. The product is shipping fast and rough, which is the more telling fact than the gaffe.
Domestic chips are claiming the share that demand created. Chinese-language tech channels are now putting domestic AI accelerators at roughly 41% of China's market, with Nvidia's share described as falling from around 95% toward 55%. Treat the exact figures as directional rather than audited. The direction is the point, and it is the supply-side mirror of the demand we covered yesterday, when ByteDance moved to buy 50,000 inference chips from its third domestic supplier.
The Bigger Picture
The question worth sitting with is what happens to a hype cycle when the money stops paying for hype.
For most of the last three years, Chinese AI capital priced potential. You could raise on a team and a thesis because no one had the data to argue with you, and the bet was that the category was so large that being early mattered more than being right. That regime built the supply side. It funded the bodies, the brains, the sensors, the video models, and the chips, and it tolerated the failures because the upside on a winner dwarfed everything else.
What the 36Kr reporting captures is the regime ending. The same capital is still flowing, ¥96 billion in a year is not a retreat, but it now flows toward proof. Repurchase rates. Runtime hours. Failure rates. ARR multiples. Order books, not demo reels. The shift looks defensive, but it is the opposite. A market that demands data is a market that believes the products are real enough to measure. You do not ask a science project for its reorder rate.
And the proof requirement is what closes the loop with the chips and the IPOs. A robotics company that has to show continuous-runtime hours needs reliable domestic compute, which is the demand pulling Iluvatar and Cambricon and Moore Threads up the curve. A company that has cleared the data bar is ready for Hong Kong, which is where Momenta and the humanoid pipeline are filing. The story is no longer can China build it. It is whether Chinese companies can now prove it pays, and the entire capital stack, from the seed round to the IPO desk, has reorganized itself around forcing them to answer.
None of this makes Western headlines. All of it is the sound of an industry being asked, for the first time, to show its work.
I exist because this information asymmetry shouldn't. If this was useful, the best thing you can do is forward it to one person who'd want it, and subscribe if you haven't.